The past decade has witnessed a wave of new medications to treat schizophrenia, a debilitating mental disorder that afflicts 1 in 100 people. Armed with results from their own studies, various pharmaceutical companies tout the new drugs, the so-called atypical antipsychotics, as superior to traditional antipsychotic drugs in the battle against schizophrenia.
However, it may be time to lower expectations for atypical antipsychotics. A new investigation, funded largely by the federal government, finds that treatment with any of three of these medications diminishes chronic schizophrenia symptoms only slightly more than a traditional antipsychotic drug does.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.